Serina Therapeutics(NYSEMKT) SER

Market Cap$62.49M

Since IPO (2024)-83%

5 Year-93%

1 Year-52%

1 Month+19%

$2.43

-1.22%

-0.03Today

After hours$2.43+$0.00 (+0.00%)

Serina Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 2.46	2026-08-28

Serina Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-14.29%	USD 2.87	2026-08-21
1 month	+18.84%	USD 2.07	2026-07-29
3 month	+33.7%	USD 1.84	2026-05-29
Year to date	+28.59%	USD 1.91	2025-12-31
1 year	-52.05%	USD 5.13	2025-08-28
3 year	-90.29%	USD 25.33	2023-08-29
5 year	-93.34%	USD 36.93	2021-08-27
Since inception	-83.46%	USD 14.87	2024-03-27

Serina Therapeutics Financials at a Glance

Market Cap

$62.49M

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.18M

EPS (TTM)

-$1.88

P/E Ratio

-1.31

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$2.43

Volume

23,116.794

Open

$2.40

Price

$2.43

Volume

23,116.794

Open

$2.40

Previous Close

$2.42

Daily Range

$2.38 - $2.50

52-Week Range

$1.22 - $5.83

Estimated Earnings Date

Nov 18, 2026

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$2.43

Volume

23,116.794

Open

$2.40

Previous Close

$2.42

Daily Range

$2.38 - $2.50

52-Week Range

$1.22 - $5.83

Estimated Earnings Date

Nov 18, 2026

SER News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Serina Therapeutics

Serina develops new drug delivery methods for neurological diseases and pain. Its products aim to help people with Parkinson’s disease, epilepsy, and chronic pain. The company’s technology also supports vaccine development for infectious diseases.

What’s in the Serina Toolbox?

SER 252: Drug candidate for advanced Parkinson’s disease, designed for weekly injection. (0% of revenue; pre-commercial)
SER 227: Long-acting pain relief drug candidate, targeting chronic pain patients. (0% of revenue; pre-commercial)
SER 214: Early-stage Parkinson’s and Restless Leg Syndrome treatment, not advanced internally. (0% of revenue; pre-commercial)
SER 228: Epilepsy drug candidate, still in development. (0% of revenue; pre-commercial)
POZ Technology: Platform for improving drug delivery and vaccine development, licensed to partners. (All revenue to date comes from grants and licensing; no product sales)

Growth Moves: Serina’s Expansion Playbook

Signed non-exclusive license with Pfizer in October 2023 for POZ technology in RNA vaccine delivery.
Partnered with Enable Injections in May 2024 to develop wearable drug delivery for SER 252.
Launched Phase 1b clinical trial for SER 252 in February 2026 after FDA clearance.
Expanded POZ-lipid research for RNA vaccines, targeting infectious disease applications since 2024.
Raised capital through private placements and convertible notes in 2025 and 2026 to fund operations.

Why Serina’s Approach Stands Out

Serina’s POZ technology offers programmable drug release and avoids immune reactions seen with older polymers. The company focuses on both internal drug development and licensing its platform to larger partners. Its small team leverages partnerships to advance research and share risk.

Five Things You Need to Know

Revenue was $0 in QQ3 2025, down 100% from QQ3 2024.
Net loss was $19.2 million for the year ended December 31, 2025, compared to $11.2 million for the same period in 2024.
Research and development expenses were $13.2 million for the year ended December 31, 2025, compared to $7.5 million for the same period in 2024.
Cash and cash equivalents were $3.1 million as of December 31, 2025.
All revenue comes from grants and licensing, with no product sales to date.

Bottom Line

Serina remains a pre-commercial biotech focused on drug delivery innovation. Its future depends on advancing clinical trials and securing new partnerships or funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Steven A. Ledger

Website

www.serinatherapeutics.com

Headquarters

Huntsville, AL 35806, US

SER Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-222.42%

Return on Capital

-15108.18%

Return on Assets

-82.03%

Earnings Yield

-76.34%

Dividend Yield

0.00%

Payout Ratio

-11.99%

Stock Overview

Market Cap

$62.49M

Shares Outstanding

25.40M

Volume

23.12K

Avg. Volume

78.11K

Financials (TTM)

Gross Profit

-$7.07M

Operating Income

-$25.66M

EBITDA

-$22.15M

Operating Cash Flow

-$21.14M

Capital Expenditure

-$66.00K

Free Cash Flow

-$21.17M

Cash & ST Invst.

$23.02M

Total Debt

$3.21M

Serina Therapeutics Performance Analysis

Serina Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 3,153,000	N/A
2024	2024-12-31	USD 56,000	-98.2%
2025	2025-12-31	USD 130,000	132.1%

Serina Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-100.0%
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Serina Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -9.70	20.4%
2023	2023-12-31	USD 0.73	N/A
2024	2024-12-31	USD -1.51	N/A
2025	2025-12-31	USD -1.91	26.0%

Serina Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	31.3%
Q4	2025-12-31	29.5%
Q1	2026-03-31	-87.1%
Q2	2026-06-30	5.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$62.49M

N/A

Market Cap/Employee

$3.91M

N/A

Employees

N/A

Net Income

-$6.36M

+1.4%

EBITDA

-$7.42M

-15.2%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$23.02M

+281.1%

Total Debt

$3.21M

+1634.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.21M

+1634.6%

Short Term Debt

$0.00

N/A

Return on Assets

-82.03%

N/A

Return on Invested Capital

-1.16%

N/A

Free Cash Flow

-$6.68M

-78.2%

Operating Cash Flow

-$6.68M

-78.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

INMBINmune Bio, Inc.

INMBINmune Bio, Inc.$2.30-1.29%

TELOTelomir Pharmaceuticals, Inc. Common Stock

TELOTelomir Pharmaceuticals, Inc. Common Stock$1.12-1.75%

ALGSAligos Therapeutics, Inc.

ALGSAligos Therapeutics, Inc.$5.86-15.20%

GRCEGrace Therapeutics, Inc.

GRCEGrace Therapeutics, Inc.$2.13+0.47%

BRNSBarinthus Biotherapeutics plc

BRNSBarinthus Biotherapeutics plc$0.70-6.61%

GNTAGenenta Science S.p.A.

GNTAGenenta Science S.p.A.$1.02+2.00%

SKYESkye Bioscience, Inc.

SKYESkye Bioscience, Inc.$1.68-5.35%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About SER

What is the current price of Serina Therapeutics?

Serina Therapeutics is trading at $2.42 per share.

What is the 52-week range for Serina Therapeutics?

Over the past 52 weeks, Serina Therapeutics has traded between $1.22 and $5.83.

How much debt does Serina Therapeutics have?

As of the most recent reporting period, Serina Therapeutics reported total debt of $3.21M.

How much cash does Serina Therapeutics have on hand?

Serina Therapeutics reported $23.02M in cash and cash equivalents in its most recent financial results.

What is Serina Therapeutics’s dividend yield?

Serina Therapeutics does not currently have a dividend yield.

Serina Therapeutics(NYSEMKT) SER

Serina Therapeutics Financials at a Glance

SER News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Serina Therapeutics

What’s in the Serina Toolbox?

Growth Moves: Serina’s Expansion Playbook

Why Serina’s Approach Stands Out

Five Things You Need to Know

Bottom Line

SER Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Serina Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SER

What is the current price of Serina Therapeutics?

What is the 52-week range for Serina Therapeutics?

How much debt does Serina Therapeutics have?

How much cash does Serina Therapeutics have on hand?

What is Serina Therapeutics’s dividend yield?

Premium Investing Services